Mexico Cell And Gene Therapy Cdmo Market Size & Outlook

The cell and gene therapy cdmo market in Mexico is expected to reach a projected revenue of US$ 113.4 million by 2030. A compound annual growth rate of 26.9% is expected of Mexico cell and gene therapy cdmo market from 2024 to 2030.
Revenue, 2023 (US$M)
$21.4
Forecast, 2030 (US$M)
$113.4
CAGR, 2024 - 2030
26.9%
Report Coverage
Mexico

Mexico cell and gene therapy cdmo market, 2018-2030 (US$M)

Mexico

Mexico cell and gene therapy cdmo market highlights

  • The Mexico cell and gene therapy cdmo market generated a revenue of USD 21.4 million in 2023 and is expected to reach USD 113.4 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 26.9% from 2024 to 2030.
  • In terms of segment, pre-clinical was the largest revenue generating by phase in 2023.
  • Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.


Cell and gene therapy cdmo market data book summary

Market revenue in 2023USD 21.4 million
Market revenue in 2030USD 113.4 million
Growth rate26.9% (CAGR from 2023 to 2030)
Largest segmentPre-clinical
Fastest growing segmentPre-clinical
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPre-clinical, Clinical
Key market players worldwideLonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc


Other key industry trends

  • In terms of revenue, Mexico accounted for 0.4% of the global cell and gene therapy cdmo market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2030.
  • Brazil is the fastest growing regional market in Latin America and is projected to reach USD 428.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy CDMO Market Companies

Name Profile # Employees HQ Website

Mexico cell and gene therapy cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.


Pre-clinical was the largest segment with a revenue share of 66.36% in 2023. Horizon Databook has segmented the Mexico cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.


According to the International Trade Administration, updated in November 2023, Mexico is the 15thlargest pharmaceutical market globally and the second largest in Latin America after Brazil. In addition, the country’s pharmaceutical market is divided into patented medicines, presenting 51% of the market; generics, presenting 35%; and over-the-counter products, with the remaining 14% by value.

Therefore, the growing pharmaceutical market promotes the demand for advanced therapeutics in Mexico, fueling the demand for cell and gene therapy CDMO. Mexico is attracting international pharmaceutical companies and CDMOs. In addition, the country provides a favorable market environment to attract R&D investment and expansion, stimulating the demand for CDMO.

Most pharmaceutical companies in the country are gradually expanding & modernizing their development and production criteria with the support of CMDO to increase local & international market supply of pharmaceuticals. Furthermore, the country’s generic & biosimilar sector is anticipated to expand in value due to the developing pharmaceutical sector and government initiatives.

Reasons to subscribe to Mexico cell and gene therapy cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Mexico cell and gene therapy cdmo market databook

  • Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Mexico cell and gene therapy cdmo market size, by by phase, 2018-2030 (US$M)

Mexico Cell And Gene Therapy CDMO Market Outlook Share, 2023 & 2030 (US$M)

Mexico cell and gene therapy cdmo market size, by by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more